Company Reports

Recent Updates

All Reports

Stock Analyst Note

LivaNova's third quarter included top-line growth of 10% in constant currency and adjusted operating income up 15% year over year. Management raised the full-year outlook for both cardiopulmonary and neuromodulation growth by 100 basis points at the midpoint, for total sales growth of 9% to 10%.
Company Report

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.
Stock Analyst Note

LivaNova delivered second-quarter results that featured revenue growth of 10% in constant currency. Operating margin fell 270 basis points thanks to unusual legal expenses. Management raised 2026 guidance for sales by 1 percentage point and earnings per share by $0.10 at the midpoint.
Company Report

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.
Company Report

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.
Company Report

As a smaller medical-device firm, Livanova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.
Company Report

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.
Stock Analyst Note

Narrow-moat LivaNova extended its strength from early in the year through the second quarter with results that slightly exceeded our expectations. With two quarters of outperformance under its belt, we expect to moderately raise our fair value estimate. We think tighter execution and the rollout of its new Essenz heart-lung machine have given LivaNova an opportunity to ramp up growth in its cardiopulmonary segment. The US market has been particularly responsive, with year-to-date growth of 29%. This strong performance and solid results from the neuromodulation business buy the new management team time to sort out the rest.
Stock Analyst Note

Narrow-moat Livanova posted first-quarter results that exceeded our expectations on the topline but were consistent with our profitability projections. We continue to hold more tempered views for slower growth in the second half of 2024, which is consistent with management's comments and, as a result, our fair value estimate is unchanged. Though quarterly revenue grew strongly at 12% year over year, below-the-line charges pushed earnings down. Considering that new CEO Vladimir Makatsaria is eager to demonstrate positive results now that he's leading the charge, we wouldn't be surprised if above-market growth could extend through the second quarter, aided by the regulatory and supply issues with oxygenators from competitors. If competitive oxygenators are able to return to the market in the second half of 2024, as expected, we anticipate Livanova's cardiopulmonary business could see noticeable moderation.
Company Report

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.
Stock Analyst Note

LivaNova delivered fourth-quarter and full-year results that ran slightly ahead of our expectations on the top line and slightly below on the bottom line largely due to impairment charges. We’re leaving our fair value estimate unchanged. Full-year revenue increased 13% in constant currency, fueled by exceptional 18% growth in cardiopulmonary, as adoption of new heart-lung machine Essenz has ramped up. We anticipate this growth to moderate in 2024 as capital spending on those platforms softens.
Stock Analyst Note

Narrow-moat LivaNova reported robust third-quarter results that ran slightly ahead of our expectations on the top line, but our slight adjustments to our near-term estimates weren’t enough to materially shift our fair value estimate. The shares remain fairly valued, in our view.
Company Report

As a smaller medical device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable, and with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal R&D, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

Sponsor Center